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INTRODUCTION
Diabetes, a chronic disorder in metabolism of 
carbohydrates, proteins, and/or fat is now epidemic 
with the worldwide incidence of 5% in the general 
population. It is estimated that the number of adults 
with diabetes in the world will rise to 300 million 
in the year 2025 (Torben, 2002). Diabetic patients 
usually experience significant morbidity and mortality 
from microvascular (retinopathy, neuropathy, and 
nephropathy) and macrovascular complications 
(heart attack, stroke, and peripheral vascular disease) 
(Engelgau et al., 2004).
The management of diabetes (especially Type 2) has evolved 
in recent times with many options available to patients. 
These include the use of sulfonylureas, the glucosidase 
inhibitors (biguanides), thiazolidinediones, insulin analogs, 
and D-phenylalanine derivatives (Christensen et al., 2009; 
Fowler, 2007). These drugs, although relatively effective, 
are not without untoward effects and are also costly. Thus, 
some patients explore the use of natural products (plants) 
for the management of diabetes. Ethnopharmacological 
studies have shown that more than 1200 plants are used 
in traditional medicine for their alleged hypoglycemic 
activity (Kesari et al., 2007).
Bridelia ferruginea Benth (Euphorbiaceae) is the common 
medicinal plant that has been widely reported for its 
pharmacological effects, especially its anti-diabetic 
properties (Iwu, 1983; Njamen et al., 2012). The clinic 
at the Center for Plant Medicine Research (CPMR), 
Mampong-Akuapem, Ghana, prescribes B. ferruginea 
tea to Type 2 diabetic patients. Unconfirmed reports 
indicate that some patients, who visit the clinic for herbal 
treatment of diabetes, continue to take their orthodox 
medication (such as metformin) alongside. This practice 
can possibly result in herb-drug interaction, an area of 
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ABSTRACT
The concurrent use of herbal medicines and orthodox drugs, especially in the treatment and management of chronic 
ailments, may result in clinically significant herb-drug interactions. Bridelia ferruginea Benth (Euphorbiaceae) 
is a common medicinal plant with known anti-diabetic properties and has been reported to be taken alongside 
the orthodox medicine, metformin. The aim of this study was to investigate the effect of aqueous extract of 
B. ferruginea leaves on the pharmacokinetics of metformin in female Sprague-Dawley rats. Reconstituted freeze 
dried extract of B. ferruginea leaves (30 mg/kg), and metformin (7 mg/kg) were administered concurrently as 
a single dose to female Sprague-Dawley rats. Whole blood samples (1 ml) were aseptically withdrawn by tail 
bleeding at 1, 2, 4, 8, and 24 h after administration of the single dose for pharmacokinetics analyses. Concurrent 
administration of metformin and B. ferruginea significantly affected (P < 0.05) all the pharmacokinetics 
parameters of metformin except for the time to attain the maximum concentration (Tmax), which increased 
but insignificantly. Whereas the area under the curve, maximum whole blood concentration (Cmax) and half-life 
(T½) of metformin decreased significantly in the presence of B. ferruginea, the elimination rate constant (Kel), 
clearance (Cl), absorption rate constant (Ka), and volume of distribution (Vd) of metformin increased significantly 
in the presence of B. ferruginea. Therefore, in clinical practice, patients should be advised on the implication of 
concurrent administration of metformin and B. ferrruginea.
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research affecting the modern practice of medicine but 
has received little attention.
Although the repercussion of herb-drug interaction 
could be beneficial or detrimental, there are no studies 
to ascertain the effect of such practice, especially on the 
pharmacokinetics of the orthodox anti-diabetic drug, 
metformin. The aim of this study, therefore, was to 
investigate the effect of aqueous extract of B. ferruginea 
leaves on the following pharmacokinetic parameters of 
metformin; concentration - Time course: The maximum 
whole blood concentration and time for the maximum 
concentration, bioavailability, elimination rate constant, 
half-life, clearance, volume of distribution and absorption 
rate constant. The outcome of this study would provide 
additional scientific information for the management of 
diabetes at the clinic of CPMR.
MATERIALS AND METHODS
Animals
A total of 20 female Sprague-Dawley rats weighing 
between 168 and 206 g were obtained from the Animal 
Unit of the CPMR, Mampong Akuapem, Ghana and 
standard laboratory chow diet was obtained from Ghana 
Agro Food Company, Tema, Ghana.
Preparation of Plant Extract
A hot infusion was made by boiling powdered leaves of 
B. ferruginea (6.49 g) in a 500 ml of water for 10-15 min 
and then decanted. The resultant extract was lyophilized 
into powder using a freeze dryer (EYELA, Tokyo Rikakikai 
Co. Ltd., Japan). The dried powdery extract was weighed 
(0.97 g) and stored in a desiccator at room temperature. 
The powder was reconstituted in distilled water before 
administration to the animals.
Experimental Design
The rats were randomly divided into four groups of five 
animals each, fed on the standard laboratory chow and 
water ad libitum, and acclimatized for a week before the 
commencement of the treatment.
Group I: Received metformin, as a single dose (7 mg/kg; 
based on the recommended dosage in humans).
Group II: Concurrently, received reconstituted freeze 
dried B. ferruginea at the therapeutic dose (30 mg/kg) 
(CSRPM, unpublished data) and a single oral dose of 
metformin.
Group III: Received reconstituted freeze dried B. ferruginea 
at the therapeutic dose (30 mg/kg).
Group IV: Received distilled water.
Blood Sampling
Whole blood samples (1 ml) of animals in each group 
were aseptically withdrawn by tail bleeding at 1, 2, 4, 
8, and 24 h after administration of the single dose of 
metformin. Blood was collected into tubes containing 
trisodium citrate as an anticoagulant and stored at –20°C 
for pharmacokinetic studies.
Extraction of Metformin from Whole Blood
The extraction of metformin from whole blood was 
carried out as described by Chhetri et al. (2014) with 
modifications. Whole blood (380 µl) was transferred into 
a 1.5 ml eppendorf tube. 20 µl of perchloric acid (60-62% 
m/m) was added and vortex mixed for 1 min. 100 µl of 
the mobile phase was then added and vortex mixed for 
1 min. The mixture was centrifuged at 9400 g for 3 min 
and the supernatant layer was transferred into another 
tube and filtered through a 0.45 µm filter. 10 µl of the 
filtrate was injected onto the high-performance liquid 
chromatography (HPLC) column. The mobile phase was 
composed of water (pH 3.2 adjusted with orthophosphoric 
acid) and acetonitrile (35:65 v/v); at a flow rate of 
0.8 ml/min with run time of 10 min.
HPLC Analysis of Metformin
Calibration curve
Standard stock solutions of 100 μg/ml of metformin were 
prepared using diluent (HPLC grade water adjusted to 
pH 3.2 with orthophosphoric acid). A calibration curve 
of metformin concentration versus peak area in the 
range of 0-10 μg/ml was prepared. Reference standard 
(0.625 μg/ml of metformin) was used to check the system 
suitability. Peak area was plotted against concentrations 
and linearity accepted for r2 ≥ 95%.
Instrumentation and conditions for chromatography
Instrumentation
An HPLC analysis of metformin was performed with 
the Agilent Chemstation HPLC system, consisting of 
1260 Quart HPLC pump, ASL Prep autosampler, and 
multiple wavelength detectors.
Chromatographic conditions
A Supelco C18 reversed phase column (250 mm × 
4.6 mm, 5 µm) was used for the chromatographic analyses 
of metformin. The mobile phase was water (pH 3.2 
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adjusted with orthophosphoric acid) and acetonitrile 
(35:65 v/v) adjusted to a flow rate of 0.6 ml/min with 
the ultraviolet detector set at 233 nm.
Pharmacokinetic Analysis
Concentration-time profiles were analyzed using non-
compartmental methods (Shargel and Yu, 1993). The 
concentration-time profile was generated from the 
original data obtained. The maximum whole blood 
concentration (Cmax) and time to Cmax (Tmax) were obtained 
directly from original data. The elimination rate constant, 
Kel, was first estimated from log-linear regression of the 
straight terminal part of the curve; in all instances this 
was made up of the last three or four concentration-time 
points.
The Kel was calculated from slope of the equation;
Log logC kt Cp po= − +/ .2 3
Where Cp is concentration at any time (t), k is the 
elimination rate constant; Cpo is the intercept on the Y-axis.
Therefore,
Slope = −k/ .2 3
The elimination half-life (t½) was calculated using the 
equation
t In Kel½ /= 2
The area under the concentration-time curve (AUC), a 
measure of bioavailability, was calculated by the trapezoidal 
rule as shown below;
AUC C C t tn n n n= − + − −[ ][ ]/1 1 2
Where, tn is the time of observation of drug concentration 
Cn, and tn−1 is the time of the prior observation of drug 
concentration corresponding to Cn−1.
The clearance rate (Cl) was calculated as Dose/AUC.
The volume of distribution (Vd) was calculated as Cl × Kel
From a concentration-time semi-log graph, the absorption 
rate constant (Ka) was estimated from the intercept of the 
equation below;
Log C Log FK D V K K kp a o d a el t= − −[( )/ ( )] / .2 3
Where, Cp is the concentration at time t, Kel is the elimation 
rate constant, Vd is the volume of distribution, Do is the 
dose and F is the fraction of the drug absorbed given as 
peak concentration divided by Dose (Shargel and Yu, 1993; 
Räth et al., 2004).
RESULTS
Samples of HPLC Chromatograms of Metformin 
Extracted from Whole Blood
A sample of the chromatogram of metformin extracted 
from whole blood is shown in Figure 1. The constituents 
of the blank blood did not interfere with the metformin 
peak (Figure 1a). The blank (drug-free whole blood) 
absorbed minimally around 2.0 min and 3.5 min but 
did not interfere with metformin peak. The retention 
time of metformin under the conditions used was 
about 3.63 ± 0.02 min (Figure 1b).
Chromatograms showing peaks after extraction of: 
Drug-free whole blood as blank (a) and metformin 
contained whole blood (b). Retention time (Rt) in 
min is shown adjacent to the peak: (Rt = 3.628). For 
HPLC condition and procedure refer to the section on 
“Method.”
Calibration Curve
Figure 2 shows the calibration curve from which the 
concentration of metformin, extracted from whole 
blood, was extrapolated. From the calibration curve, 
regression coefficient (R2) was 0.996 (99.6%). This 
signifies a strong positive correlation between the 
concentration and peak area in the HPLC analyses of 
metformin.
Figure 1: High-performance liquid chromatography chromatograms 
of metformin and blank blood after extraction
b
a
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Concentration-time Profile of Metformin in the 
Presence and Absence of B. ferruginea
Figure 3 shows the concentration-time curve of metformin 
in the presence and absence of B. ferruginea. The blood 
metformin level of the control group (metformin-treated 
group) reached its maximum level (83.36 ± 15.53 µg/
ml) after about 2 h and decreased rapidly by 82% to 
13.94 ± 0.04 µg/ml within 2 h and then gradually to 
undetectable level by 24 h (Figure 3). However, the whole 
blood metformin level of the test group (metformin and 
B. ferruginea treated group) peaked after about 2 h to 
45.08 ± 10.60 µg/ml; a lower concentration relative to 
the control. The drug level then decreased gradually to an 
undetectable level after 10 h.
Effect of aqueous extract of B. ferruginea leaves at 30 mg/
kg concentration on the whole blood levels of metformin 
given as single oral dose (7 mg/kg). Concentrations are 
given as mean ± standard error of the mean, n = 5.
Pharmacokinetic Parameters of Metformin in the 
Presence and Absence of B. ferruginea
The pharmacokinetic parameters of metformin in the 
presence and absence of B. ferruginea are shown in Table 1. 
From Table 1, concurrent administration of metformin 
and B. ferruginea significantly affected (P < 0.05) all the 
pharmacokinetics parameters of metformin except for the 
time to attain the maximum concentration (Tmax), which 
was not significantly affected. Whereas the AUC, maximum 
whole blood concentration (Cmax) and elimination half-life 
(T½) of metformin decreased significantly in the presence 
of B. ferruginea, the elimination rate constant (Kel), 
clearance (Cl), absorption rate constant (Ka), and volume 
of distribution (Vd) of metformin increased significantly 
in the presence of B. ferruginea.
DISCUSSION
The concurrent use of orthodox medicines and herbs to 
facilitate or hasten recovery especially in the treatment 
and management of chronic ailments such as diabetes, 
hypertension, HIV/AIDS and cancer is on the rise 
(Obodozie, 2012). One of the consequences of concurrent 
use of herbal medicines and orthodox medicines is the 
possibility of interactions. This study investigated the 
effect of aqueous extract of B. ferruginea leaves on the 
pharmacokinetics of metformin.
The study showed that concurrent administration 
of metformin and B. ferruginea significantly affected 
(P < 0.05) all the pharmacokinetic parameters of 
metformin except for the time to attain the maximum 
concentration (Tmax) which increased but insignificantly. 
From the study, concurrent administration of metformin 
and B. ferruginea significantly decreased the maximum 
whole blood concentration (Cmax) and AUC (a measure of 
bioavailability) of metformin although the absorption rate 
constant (Ka) of metformin increased significantly.
The observed decrease in the Cmax and bioavailability despite 
the increase in absorption rate constant could be attributed 
to the significant increase in the volume of distribution (Vd) 
of metformin in the presence of B. ferruginea. Metformin 
is reported to be widely distributed into body tissues 
such as intestine, liver and kidney via various organic 
cation transporters (Gong et al., 2012). From the study, 
in the presence of B. ferruginea, metformin appears to be 
Figure 2: Calibration curve of metformin concentration against peak 
area
Figure 3: Effect of Bridelia ferruginea on whole blood concentration 
of metformin
Table 1: Pharmacokinetic parameters of metformin administered 
as a single oral dose in the absence and presence of B. ferruginea
Pharmacokinetic 
parameter
Metformin 
alone
Metformin and 
B. ferruguinea
Comment
AUC (µg/ml−1 h−1) 223.57±28.96 123.87±37.95 Decrease
Cmax (µg/ml) 83.36±15.53 45.08±10.60 Decrease
Tmax (h) 1.80±0.20 2.40±0.40 Increase
T½ (h) 6.75±0.36 0.54±0.06 Decrease
Kel (h
−1) 0.10±0.01 1.13±0.05 Increase
Clearance (L/h) 6.60±0.65 16.10±3.97 Increase
Vd (L/kg) 0.69±0.09 18.24±3.67 Increase
Ka (h
−1) 0.15±0.01 1.33±0.17 Increase
Values are given as mean±SEM, n=5. B. ferruginea: Bridelia 
ferruginea. SEM: Standard error of mean, AUC: Area under the curve
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more distributed (about 25 times) into the body tissues 
as evident in the significant increase in Vd after concurrent 
administration of B. ferruginea and metformin. This 
observation could contribute to the observed decrease 
in Cmax and bioavailability of metformin in the presence 
of B. ferruginea.
Furthermore, two major factors contribute significantly to 
the bioavailability of a drug. These are the degree of first-
pass metabolism of the drug in the liver and intestine, and 
the extent of protein binding of the drug (Thomson, 2004). 
Unlike other biguanides, no metabolites or conjugates of 
metformin have been identified suggesting that metformin 
does not undergo liver metabolism (Scheen, 1996). Instead, 
it undergoes renal excretion. In addition, metformin 
does not bind to plasma proteins (Sambol et al., 1996). 
This suggests that the observed decrease in the Cmax and 
bioavailability could also be due to a higher rate of excretion 
of metformin. This assertion is evident in the observed 
decrease (P < 0.05) in the half-life (T½) and significant 
increase in the elimination rate constant (Kel) and clearance 
(Cl) of metformin in the presence of B. ferruginea.
Therefore, in clinical practice, patients should be advised 
on the implication of concurrent administration of 
metformin and B. ferrruginea. The study, however, cannot 
conclude with certainty the clinical effect of concurrent 
administration of metformin and B. ferrruginea since 
metformin alone and B. ferruginea alone have been reported 
to be effective anti-diabetic medicines. Thus, further work 
including efficacy studies in animals, may be carried out 
to investigate the effect of concurrent administration of 
metformin and B. ferrruginea in diabetic animal models.
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